Related Experiment Videos
Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity
1Department of Environmental Health Sciences, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland, USA.
Abstract:
We used the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to evaluate the sensitivity and specificity of the peripheral benzodiazepine receptor (PBR) as a biomarker of chemical-induced neurotoxicity. Receptor autoradiography of [3H]-PK11195, a PBR selective ligand, indicated dose-dependent increases throughout the nigrostriatal dopaminergic system as early as 24 h after MPTP administration (10-80 mg/kg), which persisted for at least 21 days. The binding of [3H]-PK11195 was increased as much as 98% in the corpus striatum and 114% in the substantia nigra, following MPTP exposure. The integrity of nigrostriatal dopaminergic terminals in the corpus striatum was assessed by measuring high affinity dopamine transporter (DAT) levels and dopamine content. DAT levels were measured by [3H]-WIN 35,428 autoradiography, and dopamine content decreased with increasing MPTP dose. Reductions of both indices of dopaminergic terminal integrity correlated with increased levels of [3H]-PK11195-binding in the striatum (r2 = 0.84 for DAT and 0.93 for dopamine content). Tyrosine hydroxylase (TH) immunohistochemistry demonstrated dose-dependent reductions of dopaminergic neurons in the substantia nigra pars compacta, with a 67% loss measured 7 days after treatment with 80 mg/kg MPTP. The loss of TH-positive neurons was correlated (r2 = 0.95) with increased levels of [3H]-PK11195 binding in the substantia nigra. These findings demonstrate that the PBR is both sensitive and specific for identifying brain regions involved in MPTP neurotoxicity.
Insights
Peripheral benzodiazepine receptor (PBR) binding increased significantly in brain regions affected by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. This demonstrates PBR
Area of Science:
- Neuroscience
- Toxicology
- Biomarker Research
Background:
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that selectively damages dopaminergic neurons.
- The peripheral benzodiazepine receptor (PBR) is implicated in neuroinflammation and neurodegeneration.
Purpose of the Study:
- To evaluate the sensitivity and specificity of PBR as a biomarker for chemical-induced neurotoxicity using MPTP.
- To assess the temporal dynamics of PBR changes following MPTP exposure.
Main Methods:
- MPTP administration to rodents at varying doses (10-80 mg/kg).
- Receptor autoradiography using [3H]-PK11195 to quantify PBR binding.
- Measurement of dopamine transporter (DAT) levels and dopamine content.
- Tyrosine hydroxylase (TH) immunohistochemistry to assess dopaminergic neuron loss.
Main Results:
- MPTP caused dose-dependent increases in [3H]-PK11195 binding in the nigrostriatal dopaminergic system, detectable within 24 hours and lasting at least 21 days.
- Increased PBR binding strongly correlated with reductions in DAT levels (r2=0.84) and dopamine content (r2=0.93).
- Dose-dependent loss of TH-positive neurons in the substantia nigra pars compacta correlated with elevated PBR binding (r2=0.95).
Conclusions:
- The peripheral benzodiazepine receptor (PBR) is a sensitive and specific biomarker for detecting neurotoxicity in specific brain regions.
- PBR imaging can identify brain areas affected by neurotoxic insults like MPTP.
- PBR serves as a valuable tool for monitoring chemical-induced neurotoxicity.